From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Dr Hung); and Fine Needle Aspiration Service, Brigham and Women's Hospital, Boston, Massachusetts, the Department of Pathology, Harvard Medical School, Boston, Massacusetts, and Bone and Soft Tissue Pathology Service, Dana Farber Cancer Institute, Boston, Massachusetts (Dr Qian).
Arch Pathol Lab Med. 2020 May;144(5):650-654. doi: 10.5858/arpa.2018-0349-RS. Epub 2019 May 9.
Histiocytic sarcoma, a rare malignant neoplasm showing morphologic and immunophenotypic features of histiocytes, is characterized typically by extranodal presentation and a dismal clinical course, particularly in patients with disseminated disease. A history of hematolymphoid disorder can be identified in a subset of patients, suggesting transdifferentiation of a preexisting hematolymphoid neoplasm in its pathogenesis. The differential diagnosis of histiocytic sarcoma includes various lymphomas, other histiocytic and dendritic cell neoplasms, carcinomas, melanomas, and pleomorphic sarcomas. Given its rarity and histologic overlap with diverse mimics, the diagnosis of histiocytic sarcoma can be extremely challenging. Recognition of morphologic clues, as well as judicious application of immunohistochemical markers to confirm its histiocytic lineage and to exclude mimics, is crucial for the diagnosis. Recent molecular studies by targeted next-generation sequencing identified recurrent alterations in the mitogen-activated protein (MAP) kinase pathway and chromatin regulators in the pathogenesis of histiocytic sarcoma and may suggest possible therapeutic targets.
组织细胞肉瘤是一种罕见的恶性肿瘤,具有组织细胞的形态学和免疫表型特征,其特征通常为结外表现和不良的临床病程,特别是在播散性疾病患者中。一部分患者存在血液淋巴系统疾病病史,提示其发病机制中存在先前存在的血液淋巴系统肿瘤的转分化。组织细胞肉瘤的鉴别诊断包括各种淋巴瘤、其他组织细胞和树突状细胞肿瘤、癌、黑色素瘤和多形性肉瘤。由于其罕见性和与多种模拟物的组织学重叠,组织细胞肉瘤的诊断极具挑战性。识别形态学线索,以及明智地应用免疫组织化学标志物来确认其组织细胞谱系并排除模拟物,对于诊断至关重要。最近通过靶向下一代测序的分子研究发现,在组织细胞肉瘤的发病机制中存在丝裂原活化蛋白(MAP)激酶途径和染色质调节剂的反复改变,这可能提示可能的治疗靶点。